Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
493.84 +1.37 (+0.28%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 493.80 -0.04 (-0.01%) 04/25/25
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
484.50
Day High
494.92
Open 492.54
Previous Close 492.47 492.47
Volume 1,561,500 1,561,500
Avg Vol 1,713,890 1,713,890
Stochastic %K 82.78% 82.78%
Weighted Alpha +20.77 +20.77
5-Day Change +4.74 (+0.97%) +4.74 (+0.97%)
52-Week Range 377.85 - 519.88 377.85 - 519.88
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,877,672
  • Shares Outstanding, K 256,790
  • Annual Sales, $ 11,020 M
  • Annual Income, $ -535,600 K
  • EBIT $ -233 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.50
  • Price/Sales 11.51
  • Price/Cash Flow N/A
  • Price/Book 7.75

Options Overview Details

View History
  • Implied Volatility 34.56% ( -0.99%)
  • Historical Volatility 22.60%
  • IV Percentile 82%
  • IV Rank 47.85%
  • IV High 52.99% on 12/18/24
  • IV Low 17.64% on 05/16/24
  • Put/Call Vol Ratio 0.88
  • Today's Volume 3,128
  • Volume Avg (30-Day) 1,958
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 34,806
  • Open Int (30-Day) 36,109

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 3.69
  • Number of Estimates 8
  • High Estimate 3.99
  • Low Estimate 3.47
  • Prior Year 4.29
  • Growth Rate Est. (year over year) -13.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
448.14 +10.20%
on 04/07/25
Period Open: 509.04
508.64 -2.91%
on 03/26/25
-15.20 (-2.99%)
since 03/25/25
3-Month
430.81 +14.63%
on 01/29/25
Period Open: 439.62
519.68 -4.97%
on 03/14/25
+54.22 (+12.33%)
since 01/24/25
52-Week
377.85 +30.70%
on 12/19/24
Period Open: 397.70
519.88 -5.01%
on 11/08/24
+96.14 (+24.17%)
since 04/25/24

Most Recent Stories

More News
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?

Investors will focus on lead drug Cabometyx’s performance when Exelixis EXEL reports first-quarter 2025 results shortly.The Zacks Consensus Estimate for sales and earnings is pegged at $502.8 million...

AZN : 69.57 (+0.03%)
VRTX : 493.84 (+0.28%)
EXEL : 37.43 (+0.59%)
ARGX : 614.76 (+2.37%)
Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect

Vertex Pharmaceuticals is set to unveil its Q1 results in the upcoming month, and analysts expect a double-digit drop in earnings.

XLV : 138.05 (+0.48%)
$SPX : 5,525.21 (+0.74%)
VRTX : 493.84 (+0.28%)
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech 's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking...

NFLX : 1,101.53 (+0.42%)
NVDA : 111.01 (+4.30%)
UBS : 30.02 (+0.70%)
VRTX : 493.84 (+0.28%)
LLY : 884.54 (+2.89%)
PFE : 22.92 (+0.61%)
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.

VRTX : 493.84 (+0.28%)
LLY : 884.54 (+2.89%)
AMGN : 280.84 (+0.36%)
Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right

President Trump isn't a fan of Fed Chairman Jerome Powell, despite nominating Powell to replace Janet Yellen in 2017. Trump recently called Powell a "major loser" on a social media post and demanded that...

D : 52.95 (-0.75%)
KR : 70.00 (-1.89%)
VRTX : 493.84 (+0.28%)
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff plans, then bounced back big once he said he would pause expanded tariffs on...

VRTX : 493.84 (+0.28%)
VEEV : 227.54 (-0.07%)
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce

Yo-yos are fun for kids. But yo-yo stock markets aren't so fun for grown-up investors. And unfortunately, there's been a lot more down "yo" recently than up "yo."

META : 547.27 (+2.65%)
VRTX : 493.84 (+0.28%)
AMZN : 188.99 (+1.31%)
Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades

That probably isn't an ancient Chinese curse as some think. However, many investors might wish that the times we live in weren't quite as interesting -- especially when it comes to the Nasdaq Composite...

COMP : 7.37 (+0.14%)
GOOG : 163.85 (+1.47%)
GOOGL : 161.96 (+1.68%)
$NASX : 17,382.94 (+1.26%)
VRTX : 493.84 (+0.28%)
ISRG : 514.59 (+1.27%)
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding...

CRSP : 38.27 (-2.15%)
VRTX : 493.84 (+0.28%)
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.

Contrary to what you might read on social media, Warren Buffett isn't a fan of tariffs. Berkshire Hathaway even recently took the unusual step of issuing a press release refuting social media claims that...

GOLD : 19.05 (-1.85%)
BRK.A : 795,760.00 (-0.17%)
BRK.B : 530.96 (-0.13%)
VRTX : 493.84 (+0.28%)
BRK.TO : 39.73 (-0.10%)
AMZN : 188.99 (+1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 508.09
2nd Resistance Point 501.51
1st Resistance Point 497.67
Last Price 493.84
1st Support Level 487.25
2nd Support Level 480.67
3rd Support Level 476.83

See More

52-Week High 519.88
Last Price 493.84
Fibonacci 61.8% 465.62
Fibonacci 50% 448.86
Fibonacci 38.2% 432.11
52-Week Low 377.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective